Harnessing complement biomarkers for precision cancer care

Area of Science:

• Oncology
• Immunology
• Biochemistry

Background:

• The tumor microenvironment (TME) significantly influences cancer progression and treatment outcomes.
• The complement system, a cascade of proteins, plays a critical role within the TME.
• Understanding complement's function in cancer is crucial for developing new diagnostic and therapeutic strategies.

Purpose of the Study:

• To review current data on the complement system's potential as a cancer biomarker.
• To explore how complement system analysis can aid in cancer detection, staging, and treatment monitoring.
• To define the evolving role of the complement system in comprehensive cancer management.

Main Methods:

• Transcriptomic analyses to classify tumors based on complement gene expression and prognostic impact.
• Immunostaining to visualize complement protein and fragment expression and deposition in tumors and TME.
• Analysis of complement activation fragments and autoantibodies in body fluids (e.g., blood) for non-invasive biomarker identification.

Main Results:

• Complement gene expression patterns correlate with tumor prognosis.
• Complement proteins and fragments are expressed and deposited within tumors and the TME.
• Circulating complement activation fragments and autoantibodies serve as non-invasive biomarkers for specific cancer types.

Conclusions:

• The complement system is a promising biomarker in oncology, offering insights into tumor biology and patient prognosis.
• Complement-based biomarkers can facilitate non-invasive cancer detection, staging, and potentially treatment monitoring.
• Further research and development of complement-targeting therapies and analytical tools are essential for integrating the complement system into clinical cancer management.